For years, the pharmaceutical industry has followed a familiar cycle: design a clinical trial, execute it, lock the database, analyze the results, and then wait for the next study to answer remaining questions. Wait for post-market surveillance to show real-world outcomes. Wait for regulators or payers to request more data before approving reimbursement. However, this…